中国医药导报2024,Vol.21Issue(15) :56-59.DOI:10.20047/j.issn1673-7210.2024.15.17

强的松片联合白芍总苷胶囊治疗激素依赖性亚急性甲状腺炎阴虚火旺证的临床研究

Clinical study of Prednisone Tablets combined with Baishao Zonggan Capsules in the treatment of steroid-dependent subacute thyroiditis syn-drome of hyperactivity of fire due to yin deficiency

朱平 陆羽 王凯 刘新亮 黄玉杰 颜婷 李鞠
中国医药导报2024,Vol.21Issue(15) :56-59.DOI:10.20047/j.issn1673-7210.2024.15.17

强的松片联合白芍总苷胶囊治疗激素依赖性亚急性甲状腺炎阴虚火旺证的临床研究

Clinical study of Prednisone Tablets combined with Baishao Zonggan Capsules in the treatment of steroid-dependent subacute thyroiditis syn-drome of hyperactivity of fire due to yin deficiency

朱平 1陆羽 2王凯 3刘新亮 4黄玉杰 5颜婷 5李鞠3
扫码查看

作者信息

  • 1. 江苏护理职业学院附属楚州中医院江苏省淮安市吴鞠通医院内分泌科,江苏淮安 223200
  • 2. 江苏盱眙县人民医院中心实验室,江苏盱眙 211700
  • 3. 南京医科大学附属淮安第一医院风湿免疫科,江苏淮安 223300
  • 4. 江苏省盱眙县人民医院内分泌科,江苏盱眙 211700
  • 5. 江苏省淮安市肿瘤医院内分泌科,江苏淮安 223200
  • 折叠

摘要

目的 探讨强的松片联合白芍总苷胶囊治疗激素依赖性亚急性甲状腺炎(SDSAT)阴虚火旺证的效果.方法 选取2019 年10 月至2023 年7月江苏省淮安市肿瘤医院收治的62 例SDSAT 阴虚火旺证患者,采用随机数字表法将其分成激素组与联合组,各31 例.激素组采用强的松片治疗每周减量5 mg,连续治疗直至停药,联合组在此基础上给予白芍总苷胶囊治疗,连续治疗8 周.观察两组治疗前后中医证候积分、红细胞沉降率(ESR)与甲状腺功能指标、炎症指标、临床疗效及不良反应总发生率.结果 治疗后,两组中医证候积分低于治疗前,且联合组低于激素组(P<0.05).治疗后,两组ESR、游离三碘甲状腺原氨酸、游离甲状腺素水平低于治疗前,且联合组低于激素组;两组促甲状腺激素水平高于治疗前,且联合组高于激素组(P<0.05).治疗后,两组转化生长因子-β1水平高于治疗前,且联合组高于激素组;两组白细胞介素-17 水平低于治疗前,且联合组低于激素组(P<0.05).联合组临床疗效优于激素组(P<0.05).两组不良反应总发生率比较,差异无统计学意义(P>0.05).结论 强的松片联合白芍总苷胶囊能够改善患者炎症水平及实验室指标,降低中医证候积分,提高临床疗效,减少复发,且不良反应少,安全性较高.

Abstract

Objective To investigate the effect of Prednisone Tablets combined with Baishao Zonggan Capsules in the treatment of Steroid-depen-dent subacute(SDSAT)thyroiditis syndrome of hyperactivity of fire due to yin deficiency.Methods A total of 62 patients with SDSATI syndrome of hyperactivity of fire due to yin deficiency admitted to Huaian Cancer Hospital,Jiangsu Province from October 2019 to July 2023 were selected and they were divided into the hormone group and the combination group by random number table method,with 31 cases in each group.The hormone group was treated with Prednisone Tablets with a reduction of 5 mg per week until the drug was discontinued,and the combined group was treated with Baishao Zonggan Capsules on this basis for eight weeks.Traditional Chinese medicine syndrome score,erythrocyte sedimentation rate(ESR),thyroid function index,inflammation index,clinical efficacy,and total incidence of adverse reactions were observed before and after treatment in the two groups.Results After treatment,the traditional Chinese medicine syndrome scores of the two groups were lower than before treatment,and those of the combined group were lower than those of the hormone group(P<0.05).After treatment,the levels of ESR,free triiodothyronine,and free thy-roxine in two groups were lower than before treatment,and those in the combined group were lower than those in the hormone group.The level of thyroid stimulating hormone in both groups was higher than before treatment,and that in combination group was higher than that in hormone group(P<0.05).After treatment,the levels of transforming growth factor-β1 in two groups was higher than before treatment,and that in the combined group was higher than that in the hormone group.The levels of interleukin-17 in both groups was lower than before treatment,and that in the com-bination group was lower than that in the hormone group(P<0.05).The clinical effect of combination group was better than that of hormone group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Pred-nisone Tablets combined with Baishao Zonggan Capsules can improve the inflammation level and laboratory indexes of patients,reduce traditional Chinese medicine syndrome scores,improve clinical efficacy,reduce re-currence,and have less adverse reactions and high safety.

关键词

激素依赖性亚急性甲状腺炎/强的松片/白芍总苷胶囊/临床疗效/不良反应

Key words

Steroid-dependent subacute thyroiditis/Prednisone Tablets/Baishao Zonggan Capsules/Clinical effect/Adverse reaction

引用本文复制引用

基金项目

江苏省卫生健康委科研项目(Z2021035)

江苏省老年健康科研项目(LKM2022071)

江苏省淮安市科技计划(HAB202247)

出版年

2024
中国医药导报
中国医学科学院

中国医药导报

CSTPCD
影响因子:1.759
ISSN:1673-7210
段落导航相关论文